OPRX OptimizeRx Corp
Price (delayed)
$7.59
Market cap
$139.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.01
Enterprise value
$160.19M
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients
Highlights
The gross profit is up by 39% year-on-year and by 8% since the previous quarter
OPRX's revenue is up by 35% year-on-year and by 6% since the previous quarter
OptimizeRx's quick ratio has shrunk by 82% YoY
The net income has declined by 25% year-on-year
Key stats
What are the main financial stats of OPRX
Market
Valuations
Earnings
Shares outstanding
18.32M
Market cap
$139.06M
Enterprise value
$160.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.93
Revenue
$83.2M
EBIT
-$21.73M
EBITDA
-$18.11M
Free cash flow
-$1.66M
Per share
Balance sheet
Liquidity
EPS
-$1.01
Free cash flow per share
-$0.09
Book value per share
$6.62
Revenue per share
$4.56
TBVPS
$2.58
Total assets
$172.88M
Total liabilities
$51.86M
Debt
$36.09M
Equity
$121.02M
Working capital
$31.01M
Debt to equity
0.3
Current ratio
3.07
Quick ratio
2.64
Net debt/EBITDA
-1.17
Margins
Efficiency
Dividend
EBITDA margin
-21.8%
Gross margin
62%
Net margin
-21.5%
Operating margin
-27.9%
Return on assets
-10.9%
Return on equity
-14.7%
Return on invested capital
-36.3%
Return on capital employed
-13.8%
Return on sales
-26.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OPRX stock price
How has the OptimizeRx stock price performed over time
Intraday
-2.69%
1 week
4.26%
1 month
-8.99%
1 year
-5.36%
YTD
-46.96%
QTD
-24.1%
Financial performance
How have OptimizeRx's revenue and profit performed over time
Revenue
$83.2M
Gross profit
$51.55M
Operating income
-$23.23M
Net income
-$17.91M
Gross margin
62%
Net margin
-21.5%
The operating income has contracted by 41% YoY but it has grown by 4.5% from the previous quarter
The gross profit is up by 39% year-on-year and by 8% since the previous quarter
OPRX's revenue is up by 35% year-on-year and by 6% since the previous quarter
The net income has declined by 25% year-on-year
Growth
What is OptimizeRx's growth rate over time
Valuation
What is OptimizeRx stock price valuation
P/E
N/A
P/B
1.15
P/S
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.93
OptimizeRx's EPS has decreased by 23% YoY
The price to book (P/B) is 74% less than the 5-year quarterly average of 4.5 and 26% less than the last 4 quarters average of 1.6
OPRX's equity is up by 4.5% year-on-year
The stock's P/S is 80% below its 5-year quarterly average of 8.6 and 34% below its last 4 quarters average of 2.6
OPRX's revenue is up by 35% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is OptimizeRx business performance
The ROIC has dropped by 70% year-on-year and by 4.3% since the previous quarter
The return on equity has declined by 27% year-on-year but it rose by 2% since the previous quarter
OptimizeRx's ROS has decreased by 12% YoY but it has increased by 8% from the previous quarter
The return on assets rose by 8% since the previous quarter
Dividends
What is OPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OPRX.
Financial health
How did OptimizeRx financials performed over time
OptimizeRx's quick ratio has shrunk by 82% YoY
The current ratio has plunged by 80% YoY but it has grown by 7% from the previous quarter
The debt is 70% smaller than the equity
OPRX's equity is up by 4.5% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.